HCA Healthcare, Inc. (NYSE:HCA) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,480,000 shares, a decrease of 15.9% from the March 31st total of 2,950,000 shares. Based on an average trading volume of 1,610,000 shares, the short-interest ratio is presently 1.5 days. Currently, 0.9% of the shares of the stock are sold short.
Shares of HCA Healthcare stock traded up $2.06 during trading hours on Tuesday, hitting $206.57. 38,920 shares of the company were exchanged, compared to its average volume of 1,571,990. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 23.70. The stock has a market capitalization of $69.60 billion, a price-to-earnings ratio of 20.68, a P/E/G ratio of 1.28 and a beta of 1.58. The business has a 50-day moving average of $192.13 and a 200-day moving average of $168.60. HCA Healthcare has a 1 year low of $91.21 and a 1 year high of $205.63.
HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Thursday, April 22nd. The company reported $4.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.35 by $0.79. The firm had revenue of $13.98 billion during the quarter, compared to analysts’ expectations of $13.58 billion. HCA Healthcare had a net margin of 6.70% and a return on equity of 2,032.72%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.33 earnings per share. As a group, research analysts anticipate that HCA Healthcare will post 7.01 earnings per share for the current fiscal year.
In other news, SVP Robert A. Waterman sold 147,534 shares of the business’s stock in a transaction dated Friday, April 30th. The shares were sold at an average price of $200.68, for a total transaction of $29,607,123.12. Following the completion of the sale, the senior vice president now owns 270,090 shares of the company’s stock, valued at $54,201,661.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Jonathan B. Perlin sold 37,305 shares of the stock in a transaction on Friday, April 23rd. The shares were sold at an average price of $200.03, for a total value of $7,462,119.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 430,052 shares of company stock valued at $83,589,243. Insiders own 1.80% of the company’s stock.
Several hedge funds have recently bought and sold shares of HCA. Envestnet Asset Management Inc. boosted its position in HCA Healthcare by 292.0% during the first quarter. Envestnet Asset Management Inc. now owns 246,192 shares of the company’s stock worth $46,368,000 after purchasing an additional 183,392 shares in the last quarter. Mount Yale Investment Advisors LLC increased its holdings in HCA Healthcare by 4.5% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 5,658 shares of the company’s stock valued at $1,066,000 after acquiring an additional 242 shares in the last quarter. Alamar Capital Management LLC lifted its holdings in shares of HCA Healthcare by 7.8% in the first quarter. Alamar Capital Management LLC now owns 17,639 shares of the company’s stock valued at $3,322,000 after purchasing an additional 1,275 shares in the last quarter. MJP Associates Inc. ADV acquired a new stake in HCA Healthcare during the 1st quarter valued at $216,000. Finally, Robeco Schweiz AG raised its holdings in shares of HCA Healthcare by 58.7% in the first quarter. Robeco Schweiz AG now owns 21,380 shares of the company’s stock worth $4,027,000 after acquiring an additional 7,906 shares during the last quarter. Institutional investors own 68.69% of the company’s stock.
Several brokerages have recently commented on HCA. Deutsche Bank Aktiengesellschaft upped their price objective on shares of HCA Healthcare from $210.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, April 26th. BMO Capital Markets boosted their price objective on HCA Healthcare from $200.00 to $222.00 and gave the company a “market perform” rating in a report on Monday. UBS Group boosted their price target on shares of HCA Healthcare from $164.00 to $203.00 and gave the stock a “buy” rating in a research note on Thursday, February 4th. Barclays increased their target price on shares of HCA Healthcare from $195.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, April 23rd. They noted that the move was a valuation call. Finally, Mizuho lifted their target price on HCA Healthcare from $205.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, April 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $200.10.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.